Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2006 3
2007 12
2008 25
2009 48
2010 52
2011 51
2012 68
2013 66
2014 88
2015 84
2016 82
2017 69
2018 101
2019 113
2020 136
2021 164
2022 144
2023 139
2024 48

Text availability

Article attribute

Article type

Publication date

Search Results

1,298 results

Results by year

Filters applied: . Clear all
The following terms were ignored: "", OR
Page 1
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, Weinstein B, Valdez J, Lotter J, Feng X, Desierto M, Leuva H, Bevans M, Wu C, Larochelle A, Calvo KR, Dunbar CE, Young NS. Townsley DM, et al. N Engl J Med. 2017 Apr 20;376(16):1540-1550. doi: 10.1056/NEJMoa1613878. N Engl J Med. 2017. PMID: 28423296 Free PMC article. Clinical Trial.
We combined standard immunosuppressive therapy with eltrombopag in previously untreated patients with severe aplastic anemia. METHODS: We enrolled 92 consecutive patients in a prospective phase 1-2 study of immunosuppressive therapy plus eltrombopag. The three conse …
We combined standard immunosuppressive therapy with eltrombopag in previously untreated patients with severe aplastic anemia. METHODS …
Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
Gilreath J, Lo M, Bubalo J. Gilreath J, et al. Drugs. 2021 Jul;81(11):1285-1305. doi: 10.1007/s40265-021-01553-7. Epub 2021 Jun 23. Drugs. 2021. PMID: 34160821 Free PMC article. Review.
The thrombopoietin receptor agonists (TPO-RAs) romiplostim, eltrombopag, avatrombopag, and lusutrombopag carry unique US Food and Drug Administration (US FDA)- and European Medicines Agency (EMA)-approved indications and may be used to increase platelet counts in a variety …
The thrombopoietin receptor agonists (TPO-RAs) romiplostim, eltrombopag, avatrombopag, and lusutrombopag carry unique US Food and Dru …
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Giai V, Poloni A, Patriarca A, Crisà E, Capodanno I, Salutari P, Reda G, Cascavilla N, Ferrero D, Guarini A, Tripepi G, Iannì G, Russo E, Castelli A, Fattizzo B, Beltrami G, Bocchia M, Molteni A, Fenaux P, Germing U, Ricco A, Palumbo GA, Impera S, Di Renzo N, Rivellini F, Buccisano F, Stamatoullas-Bastard A, Liberati AM, Candoni A, Delfino IM, Arcadi MT, Cufari P, Rizzo L, Bova I, D'Errigo MG, Zini G, Latagliata R. Oliva EN, et al. J Clin Oncol. 2023 Oct 1;41(28):4486-4496. doi: 10.1200/JCO.22.02699. Epub 2023 Jun 9. J Clin Oncol. 2023. PMID: 37294914 Free PMC article. Clinical Trial.
AML evolution and/or disease progression occurred in 17% (for both) of eltrombopag and placebo patients with no difference in survival times. CONCLUSION: Eltrombopag was effective and relatively safe in low-risk MDS with severe thrombocytopenia. ...
AML evolution and/or disease progression occurred in 17% (for both) of eltrombopag and placebo patients with no difference in surviva …
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Wojdyla M, Vredenburg M, Cuker A. Al-Samkari H, et al. Br J Haematol. 2022 May;197(3):359-366. doi: 10.1111/bjh.18081. Epub 2022 Feb 18. Br J Haematol. 2022. PMID: 35179784 Free PMC article.
Limited data are available describing outcomes in patients who switched from romiplostim or eltrombopag to avatrombopag, a newer oral TPO-RA. We performed a retrospective observational study of adults with ITP who switched from eltrombopag or romiplostim to avatromb …
Limited data are available describing outcomes in patients who switched from romiplostim or eltrombopag to avatrombopag, a newer oral …
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Cheng G, et al. Lancet. 2011 Jan 29;377(9763):393-402. doi: 10.1016/S0140-6736(10)60959-2. Epub 2010 Aug 23. Lancet. 2011. PMID: 20739054 Clinical Trial.
BACKGROUND: Eltrombopag is an oral thrombopoietin receptor agonist for the treatment of thrombocytopenia. ...Nine (7%) eltrombopag-treated patients and two (3%) in the placebo group had mild increases in alanine aminotransferase concentration, and five (4%) eltro …
BACKGROUND: Eltrombopag is an oral thrombopoietin receptor agonist for the treatment of thrombocytopenia. ...Nine (7%) eltrombopag …
Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB. Wong RSM, et al. Blood. 2017 Dec 7;130(23):2527-2536. doi: 10.1182/blood-2017-04-748707. Epub 2017 Oct 17. Blood. 2017. PMID: 29042367 Free article. Clinical Trial.
In phase 2/3 trials, eltrombopag treatment of 6 months or less in patients with chronic/persistent immune thrombocytopenia (ITP) increased platelet counts and reduced bleeding. The open-label EXTEND study evaluated long-term safety and efficacy of eltrombopag in adu …
In phase 2/3 trials, eltrombopag treatment of 6 months or less in patients with chronic/persistent immune thrombocytopenia (ITP) incr …
Eltrombopag.
Bussel JB, Pinheiro MP. Bussel JB, et al. Cancer Treat Res. 2011;157:289-303. doi: 10.1007/978-1-4419-7073-2_17. Cancer Treat Res. 2011. PMID: 21052963 Review.
Discovered in the middle of last decade, followed by experiments in mice and then approved in humans, Eltrombopag is the first TPO-r mimetic available. It has been used and validated in several clinical studies in different etiologies of thrombocytopenia, including primary …
Discovered in the middle of last decade, followed by experiments in mice and then approved in humans, Eltrombopag is the first TPO-r …
Preparation and Solid-State Characterization of Eltrombopag Crystal Phases.
Abbinante VM, Zampieri M, Barreca G, Masciocchi N. Abbinante VM, et al. Molecules. 2020 Dec 25;26(1):65. doi: 10.3390/molecules26010065. Molecules. 2020. PMID: 33375645 Free PMC article.
Eltrombopag, of C(25)H(22)N(4)O(4) chemical formula, is a drug used against thrombocytopenia, marketed worldwide under different tradenames in the form of its bis-olamine salt. The free acid (CAS no. 496775-61-2) is an intermediate species used for the …
Eltrombopag, of C(25)H(22)N(4)O(4) chemical formula, is a drug used against thrombocytopenia, marketed worldwide under different trad …
Eltrombopag.
Garnock-Jones KP, Keam SJ. Garnock-Jones KP, et al. Drugs. 2009;69(5):567-76. doi: 10.2165/00003495-200969050-00005. Drugs. 2009. PMID: 19368418
In addition, the proportion of patients with ITP achieving a platelet count of >200 000 cells/microL and discontinuing treatment due to protocol-defined treatment-cessation criteria, was approximately 8-fold higher with eltrombopag than with placebo. Eltrombopag …
In addition, the proportion of patients with ITP achieving a platelet count of >200 000 cells/microL and discontinuing treatment due to p …
Efficacy of Eltrombopag with Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone on Severe Aplastic Anaemia: A Systematic Review and Meta-analysis.
Zhang S, Wang Q, Cui K, Cheng B, Fan J, Hu S. Zhang S, et al. Clin Drug Investig. 2023 May;43(5):315-324. doi: 10.1007/s40261-023-01266-7. Epub 2023 May 11. Clin Drug Investig. 2023. PMID: 37165250 Free PMC article.
Therefore, we conducted this meta-analysis to compare the efficacy of eltrombopag + IST with that of IST alone in patients with SAA and to assess the difference in the efficacy of eltrombopag in adults and children. ...CONCLUSION: This meta-analysis indicated that p …
Therefore, we conducted this meta-analysis to compare the efficacy of eltrombopag + IST with that of IST alone in patients with SAA a …
1,298 results